Janux Therapeutics, Inc. (JANX)
| Market Cap | 1.14B |
| Revenue (ttm) | 862,000 |
| Net Income (ttm) | n/a |
| Shares Out | 10.03M |
| EPS (ttm) | -3.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,066,192 |
| Open | 34.00 |
| Previous Close | 34.35 |
| Day's Range | 26.80 - 34.93 |
| 52-Week Range | 16.32 - 37.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 35.00 (+27.8%) |
| Est. Earnings Date | Oct 18, 2021 |
About JANX
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), an emerging class of immunotherapies that bridge a tumor cell and a T cell, to activate and redirect T cells to attack and eliminate tumors, and our lead product candidates are designed to target clinically validated drug targets. We are d...
Financial Performance
Financial StatementsNews
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to it...
Janux Therapeutics Reports Second Quarter 2021 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today re...
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Shahram Salek...
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase...
LA JOLLA, Calif.--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the closing of its previo...
Merck Partners With Newly Public Cancer Biotech
The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).
Janux Therapeutics Announces Pricing of Initial Public Offering
Janux Therapeutics, Inc. (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the pricing of its initial public offering of 11,400,000 shares of its comm...
Janux Therapeutics IPO Registration Document (S-1)
Janux Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.